



## Caplyta® (lumateperone) – New indication

- On December 20, 2021, [Intra-Cellular Therapies announced](#) the FDA approval of [Caplyta \(lumateperone\)](#), for the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate.
- Caplyta is also approved for the treatment of schizophrenia in adults.
- The approval of Caplyta, as monotherapy, for the new indication was based on a randomized, double-blind, placebo-controlled study in 381 adult patients with depressive episodes associated with bipolar I or bipolar II disorder. The primary endpoint was the change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) total score at week 6. The MADRS is a 10-item clinician-rated scale with total scores ranging from 0 (no depressive features) to 60 (maximum score).
  - The least squares mean change from baseline in the MADRS total score was -16.7 with Caplyta vs. -12.1 with placebo (difference -4.6, 95% CI: -6.3, -2.8).
- The approval of Caplyta, as adjunctive therapy with lithium or valproate, for the new indication was based on a randomized, double-blind, placebo-controlled study in 529 adult patients with depressive episodes associated with bipolar I or bipolar II disorder. The primary endpoint was the change from baseline in MADRS total score at week 6.
  - The least squares mean change from baseline in the MADRS total score was -16.9 with Caplyta plus lithium or valproate vs. -14.5 with placebo plus lithium or valproate (difference -2.4, 95% CI: -4.4, -0.4).
- Caplyta carries a boxed warning for increased mortality in elderly patients with dementia-related psychosis and suicidal thoughts and behaviors.
- The most common adverse reactions ( $\geq 5\%$  and greater than twice placebo) with Caplyta use for bipolar depression were somnolence/sedation, dizziness, nausea, and dry mouth.
- The recommended dose of Caplyta for the treatment of schizophrenia and bipolar depression is 42 mg administered orally once daily. Dose titration is not required.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.